Slingshot members are tracking this event:
Ionis Pharmaceuticals earns 2.15M payment, on track for Phase 3 clinical Nusinersen trials
Do you think this event is important to the companies below? How will it affect their stock price?
clinicaltrials.gov record in source
Slingshot Insights Explained
Jan 12, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Spinal Muscular Atrophy, Phase 3 Clinical Trials, Phase 3 Nusinersen Trial, Nusinersen